ID   Daudi
AC   CVCL_0008
SY   DAUDI; NK-10A; NK-10a; NK 10a; NK10a; GM03190; GM3190; GM03190A; GM17346
DR   BTO; BTO:0001561
DR   CLO; CLO_0002708
DR   CLO; CLO_0013411
DR   CLO; CLO_0013740
DR   CLO; CLO_0050991
DR   EFO; EFO_0002169
DR   MCCL; MCC:0000141
DR   CLDB; cl993
DR   CLDB; cl994
DR   CLDB; cl995
DR   CLDB; cl996
DR   CLDB; cl997
DR   CLDB; cl998
DR   CLDB; cl999
DR   CLDB; cl5181
DR   AddexBio; C0003010/4669
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CCL-213
DR   BCRC; 60192
DR   BioSample; SAMN01821546
DR   BioSample; SAMN01821623
DR   BioSample; SAMN03472413
DR   BioSample; SAMN10987948
DR   CCRID; 3111C0001CCC000134
DR   CCRID; 3111C0002000000053
DR   CCRID; 3131C0001000700140
DR   CCRID; 3142C0001000000082
DR   Cell_Model_Passport; SIDM00845
DR   CGH-DB; 9195-4
DR   ChEMBL-Cells; CHEMBL3307579
DR   ChEMBL-Targets; CHEMBL614281
DR   Coriell; GM03190
DR   Coriell; GM17346
DR   Cosmic; 687838
DR   Cosmic; 906831
DR   Cosmic; 919135
DR   Cosmic; 929815
DR   Cosmic; 931102
DR   Cosmic; 932762
DR   Cosmic; 991548
DR   Cosmic; 996304
DR   Cosmic; 998716
DR   Cosmic; 1019315
DR   Cosmic; 1037701
DR   Cosmic; 1070708
DR   Cosmic; 1071878
DR   Cosmic; 1086326
DR   Cosmic; 1118470
DR   Cosmic; 1176616
DR   Cosmic; 1191690
DR   Cosmic; 1517663
DR   Cosmic; 1995384
DR   Cosmic; 2649240
DR   Cosmic-CLP; 906831
DR   dbMHC; 48767
DR   DepMap; ACH-000786
DR   ECACC; 85011437
DR   ECACC; 94071449
DR   GDSC; 906831
DR   GEO; GSM99381
DR   GEO; GSM862859
DR   GEO; GSM862860
DR   GEO; GSM862861
DR   GEO; GSM862862
DR   GEO; GSM886973
DR   GEO; GSM888042
DR   GEO; GSM960117
DR   GEO; GSM960118
DR   GEO; GSM960119
DR   GEO; GSM960120
DR   GEO; GSM1374459
DR   GEO; GSM1669726
DR   IARC_TP53; 143
DR   ICLC; HTL95024
DR   IGRhCellID; Daudi
DR   IHW; IHW09366
DR   IPD-IMGT/HLA; 10471
DR   KCB; KCB 2012116YJ
DR   KCLB; 10213
DR   LiGeA; CCLE_233
DR   Lonza; 490
DR   NCBI_Iran; C112
DR   PharmacoDB; Daudi_283_2019
DR   RCB; RCB1640
DR   TKG; TKG 0362
DR   Wikidata; Q54828579
RX   CelloPub=CLPUB00447;
RX   PubMed=170370;
RX   PubMed=216485;
RX   PubMed=2052620;
RX   PubMed=2140233;
RX   PubMed=3034807;
RX   PubMed=3080238;
RX   PubMed=3518877;
RX   PubMed=3785169;
RX   PubMed=4122458;
RX   PubMed=4174339;
RX   PubMed=4178827;
RX   PubMed=4321974;
RX   PubMed=4364259;
RX   PubMed=5021706;
RX   PubMed=6200433;
RX   PubMed=6286763;
RX   PubMed=6500159;
RX   PubMed=6547209;
RX   PubMed=6582512;
RX   PubMed=6935474;
RX   PubMed=7316467;
RX   PubMed=7849311;
RX   PubMed=8197130;
RX   PubMed=8301159;
RX   PubMed=8515068;
RX   PubMed=8558913;
RX   PubMed=8558920;
RX   PubMed=8847894;
RX   PubMed=9473234;
RX   PubMed=9510473;
RX   PubMed=9685479;
RX   PubMed=9737686;
RX   PubMed=9738977;
RX   PubMed=9973220;
RX   PubMed=11021758;
RX   PubMed=11894933;
RX   PubMed=12967475;
RX   PubMed=14504097;
RX   PubMed=15028022;
RX   PubMed=19358282;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20454443;
RX   PubMed=22460905;
RX   PubMed=22885699;
RX   PubMed=25355872;
RX   PubMed=25485619;
RX   PubMed=25960936;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29892436;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
CC   Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: Human variation panel.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Africans south of the Sahara.
CC   Doubling time: 23.7 hours (PubMed=8847894); ~48 hours (DSMZ).
CC   HLA typing: A*66:01,01:02; B*58:01,35:01; C*03:02,06:02; DQA1*01:03,01:03; DQB1*06:13,06:13; DRB1*13:02,03:27 (PubMed=25960936).
CC   HLA typing: A*66:01,01:02; B*58:01:01:01,58:02:01; C*03:02:02:01,06:02; DPA1*01:03:01,02:01:01:01; DPB1*02:01:02:01,106:01; DQA1*01:02,01:03; DQB1*06:04:01,06:02; DRB1*13:01:01,13:02:01; DRB3*02:02,03:01:01; DRB6*02 (IPD-IMGT/HLA; 10471).
CC   Microsatellite instability: Instable (MSI-low) (Sanger).
CC   Sequence variation: Homozygous for B2M p.Met1Ile (c.3G>C) (PubMed=8197130; PubMed=11894933; Cosmic-CLP).
CC   Sequence variation: Homozygous for CTNNB1 p.Ala5_Ala80del (c.14_241del228) (ATCC).
CC   Sequence variation: TP53 p.Arg213Ter (c.637C>T) (PubMed=2052620).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=91.6%; Native American=0.12%; East Asian, North=2.24%; East Asian, South=0%; South Asian=1.3%; European, North=0%; European, South=4.74% (PubMed=30894373).
ST   Source(s): AddexBio; ATCC; CCRID; Cosmic-CLP; DSMZ; KCLB; PubMed=25877200; RCB; TKG
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11,12
ST   D16S539: 10,12
ST   D18S51: 16,18
ST   D19S433: 12,14
ST   D21S11: 34,35
ST   D2S1338: 17,24
ST   D3S1358: 16,18
ST   D5S818: 8,13
ST   D7S820: 8,10
ST   D8S1179: 14
ST   FGA: 21,26
ST   Penta D: 10,12
ST   Penta E: 7,9 (PubMed=25877200)
ST   Penta E: 9 (CCRID)
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 15,17
DI   NCIt; C27694; Epstein-Barr virus-related Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   16Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-19; Version: 32
RX   CelloPub=CLPUB00447;
RA   Mulivor R.A., Suchy S.F.;
RT   "1992/1993 catalog of cell lines. NIGMS human genetic mutant cell
RT   repository. 16th edition. October 1992.";
RL   (In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992).
RX   PubMed=170370; DOI=10.1099/0022-1317-28-2-207;
RA   Adams A., Strander H., Cantell K.;
RT   "Sensitivity of the Epstein-Barr virus transformed human lymphoid cell
RT   lines to interferon.";
RL   J. Gen. Virol. 28:207-217(1975).
RX   PubMed=216485;
RA   Higgins N.P., Strauss B.S.;
RT   "Differences in the ability of human lymphoblastoid lines to exclude
RT   bromodeoxyuridine and in their sensitivity to methyl methanesulfonate
RT   and to incorporated [3H]thymidine.";
RL   Cancer Res. 39:312-320(1979).
RX   PubMed=2052620; DOI=10.1073/pnas.88.12.5413;
RA   Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A.,
RA   Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.;
RT   "p53 mutations in human lymphoid malignancies: association with
RT   Burkitt lymphoma and chronic lymphocytic leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991).
RX   PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x;
RA   Nakano A., Harada T., Morikawa S., Kato Y.;
RT   "Expression of leukocyte common antigen (CD45) on various human
RT   leukemia/lymphoma cell lines.";
RL   Acta Pathol. Jpn. 40:107-115(1990).
RX   PubMed=3034807; DOI=10.1002/ijc.2910390622;
RA   Ohno H., Fukuhara S., Takahashi R., Mihara K.-I., Sugiyama T., Doi S.,
RA   Uchino H., Toyoshima K.;
RT   "c-yes and bcl-2 genes located on 18q21.3 in a follicular lymphoma
RT   cell line carrying a t(14;18) chromosomal translocation.";
RL   Int. J. Cancer 39:785-788(1987).
RX   PubMed=3080238;
RA   Sieverts H., Alabaster O., Goldschmidts W., Magrath I.T.;
RT   "Expression of surface antigens during the cell cycle in different
RT   growth phases of American and African Burkitt's lymphoma cell lines.";
RL   Cancer Res. 46:1182-1188(1986).
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
RX   PubMed=3785169; DOI=10.1128/MCB.6.5.1374;
RA   Dron M., Modjtahedi N., Brison O., Tovey M.G.;
RT   "Interferon modulation of c-myc expression in cloned Daudi cells:
RT   relationship to the phenotype of interferon resistance.";
RL   Mol. Cell. Biol. 6:1374-1378(1986).
RX   PubMed=4122458; DOI=10.1002/ijc.2910100108;
RA   Klein G., Dombos L., Gothoskar B.;
RT   "Sensitivity of Epstein-Barr virus (EBV) producer and non-producer
RT   human lymphoblastoid cell lines to superinfection with EB-virus.";
RL   Int. J. Cancer 10:44-57(1972).
RX   PubMed=4174339;
RA   Klein E., Klein G., Nadkarni J.S., Nadkarni J.J., Wigzell H.,
RA   Clifford P.;
RT   "Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and
RT   in derived culture lines.";
RL   Cancer Res. 28:1300-1310(1968).
RX   PubMed=4178827; DOI=10.1002/1097-0142(196901)23:1<64::AID-CNCR2820230107>3.0.CO;2-M;
RA   Nadkarni J.S., Nadkarni J.J., Clifford P., Manolov G., Fenyo E.-M.,
RA   Klein E.;
RT   "Characteristics of new cell lines derived from Burkitt lymphomas.";
RL   Cancer 23:64-79(1969).
RX   PubMed=4321974;
RA   Maurer B.A., Wilbert S.M., Imamura T.;
RT   "Incidence of EB virus-containing cells in primary and secondary
RT   clones of several Burkitt lymphoma cell lines.";
RL   Cancer Res. 30:2870-2875(1970).
RX   PubMed=4364259; DOI=10.1002/ijc.2910110210;
RA   Klein G., Dombos L.;
RT   "Relationship between the sensitivity of EBV-carrying lymphoblastoid
RT   lines to superinfection and the inducibility of the resident viral
RT   genome.";
RL   Int. J. Cancer 11:327-337(1973).
RX   PubMed=5021706;
RA   van Furth R., Gorter H., Nadkarni J.S., Nadkarni J.J., Klein E.,
RA   Clifford P.;
RT   "Synthesis of immunoglobulins by biopsied tissues and cell lines from
RT   Burkitt's lymphoma.";
RL   Immunology 22:847-857(1972).
RX   PubMed=6200433; DOI=10.1007/BF00364762;
RA   Brodsky F.M.;
RT   "A matrix approach to human class II histocompatibility antigens:
RT   reactions of four monoclonal antibodies with the products of nine
RT   haplotypes.";
RL   Immunogenetics 19:179-194(1984).
RX   PubMed=6286763;
RA   Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd H.D.,
RA   Parsons R.G.;
RT   "Immunoglobulin secretion by cell lines derived from African and
RT   American undifferentiated lymphomas of Burkitt's and non-Burkitt's
RT   type.";
RL   J. Immunol. 129:1336-1342(1982).
RX   PubMed=6500159; DOI=10.1159/000163283;
RA   Gershwin M.E., Lentz D., Owens R.B.;
RT   "Relationship between karyotype of tissue culture lines and
RT   tumorigenicity in nude mice.";
RL   Exp. Cell Biol. 52:361-370(1984).
RX   PubMed=6547209; DOI=10.1038/309592a0;
RA   Rabbitts T.H., Forster A., Hamlyn P., Baer R.;
RT   "Effect of somatic mutation within translocated c-myc genes in
RT   Burkitt's lymphoma.";
RL   Nature 309:592-597(1984).
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
RX   PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x;
RA   Povey S., Jeremiah S., Arthur E., Steel M., Klein G.;
RT   "Differences in genetic stability between human cell lines from
RT   patients with and without lymphoreticular malignancy.";
RL   Ann. Hum. Genet. 44:119-133(1980).
RX   PubMed=7849311;
RA   Stranks G., Height S.E., Mitchell P., Jadayel D., Yuille M.A.,
RA   De Lord C., Clutterbuck R.D., Treleaven J.G., Powles R.L.,
RA   Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D.,
RA   Millar J.L., Catovsky D., Dyer M.J.S.;
RT   "Deletions and rearrangement of CDKN2 in lymphoid malignancy.";
RL   Blood 85:893-901(1995).
RX   PubMed=8197130; DOI=10.1073/pnas.91.11.4751;
RA   Bicknell D.C., Rowan A., Bodmer W.F.;
RT   "Beta 2-microglobulin gene mutations: a study of established
RT   colorectal cell lines and fresh tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:4751-4755(1994).
RX   PubMed=8301159; DOI=10.1089/jir.1993.13.377;
RA   Dron M., Tovey M.G.;
RT   "Interferon-resistant Daudi cells are deficient in
RT   interferon-alpha-induced ISGF3 alpha activation, but remain sensitive
RT   to the interferon-alpha-induced increase in ISGF3 gamma content.";
RL   J. Interferon Res. 13:377-383(1993).
RX   PubMed=8515068;
RA   Jain V.K., Judde J.-G., Max E.E., Magrath I.T.;
RT   "Variable IgH chain enhancer activity in Burkitt's lymphomas suggests
RT   an additional, direct mechanism of c-myc deregulation.";
RL   J. Immunol. 150:5418-5428(1993).
RX   PubMed=8558913;
RA   Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M.,
RA   Imaizumi M., Endo M., Takano N., Konno T.;
RT   "Cell surface c-kit receptors in human leukemia cell lines and
RT   pediatric leukemia: selective preservation of c-kit expression on
RT   megakaryoblastic cell lines during adaptation to in vitro culture.";
RL   Leukemia 10:102-105(1996).
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
RX   PubMed=8847894;
RA   Tani A., Tatsumi E., Nakamura F., Kumagai S., Kosaka Y., Sano K.,
RA   Nakamura H., Amakawa R., Ohno H.;
RT   "Sensitivity to dexamethasone and absence of bcl-2 protein in
RT   Burkitt's lymphoma cell line (Black93) derived from a patient with
RT   acute tumor lysis syndrome: comparative study with other BL and non-BL
RT   lines.";
RL   Leukemia 10:1592-1603(1996).
RX   PubMed=9473234;
RA   Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.;
RT   "p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a
RT   mRNA and protein expression in Burkitt's lymphoma.";
RL   Blood 91:1680-1687(1998).
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
RX   PubMed=9685479; DOI=10.1093/nar/26.16.3651;
RA   Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T.,
RA   Roos G.;
RT   "Telomere analysis by fluorescence in situ hybridization and flow
RT   cytometry.";
RL   Nucleic Acids Res. 26:3651-3656(1998).
RX   PubMed=9737686; DOI=10.1038/sj.leu.2401112;
RA   Zhang W., Ohnishi K., Shigeno K., Fujisawa S., Naito K., Nakamura S.,
RA   Takeshita K., Takeshita A., Ohno R.;
RT   "The induction of apoptosis and cell cycle arrest by arsenic trioxide
RT   in lymphoid neoplasms.";
RL   Leukemia 12:1383-1391(1998).
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
RX   PubMed=9973220;
RA   Gutierrez M.I., Cherney B., Hussain A., Mostowski H., Tosato G.,
RA   Magrath I.T., Bhatia K.;
RT   "Bax is frequently compromised in Burkitt's lymphomas with
RT   irreversible resistance to Fas-induced apoptosis.";
RL   Cancer Res. 59:696-703(1999).
RX   PubMed=11021758; DOI=10.1038/sj.leu.2401891;
RA   Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A.,
RA   Gaulton G.N., Ratajczak M.Z.;
RT   "Biological significance of the expression of HIV-related chemokine
RT   coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic
RT   cell lines.";
RL   Leukemia 14:1821-1832(2000).
RX   PubMed=11894933; DOI=10.1002/j.1460-2075.1983.tb01412.x;
RA   Rosa F., Berissi H., Weissenbach J., Maroteaux L., Fellous M.,
RA   Revel M.;
RT   "The beta2-microglobulin mRNA in human Daudi cells has a mutated
RT   initiation codon but is still inducible by interferon.";
RL   EMBO J. 2:239-243(1983).
RX   PubMed=12967475; DOI=10.1111/j.1349-7006.2003.tb01518.x;
RA   Maesako Y., Uchiyama T., Ohno H.;
RT   "Comparison of gene expression profiles of lymphoma cell lines from
RT   transformed follicular lymphoma, Burkitt's lymphoma and de novo
RT   diffuse large B-cell lymphoma.";
RL   Cancer Sci. 94:774-781(2003).
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric
RT   ALL with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
RX   PubMed=15028022; DOI=10.1111/j.1440-1827.2004.01612.x;
RA   Kamimura K., Hojo H., Abe M.;
RT   "Characterization of expression of protein kinase C isozymes in human
RT   B-cell lymphoma: relationship between its expression and prognosis.";
RL   Pathol. Int. 54:224-230(2004).
RX   PubMed=19358282; DOI=10.1002/ijc.24351;
RA   Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M.,
RA   Mori F., Ding J., Komatsu H., Iida S., Ueda R.;
RT   "Expression of the ULBP ligands for NKG2D by B-NHL cells plays an
RT   important role in determining their susceptibility to
RT   rituximab-induced ADCC.";
RL   Int. J. Cancer 125:212-221(2009).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=20454443; DOI=10.1155/2010/904767;
RA   Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.;
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767-904767(2010).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=22885699; DOI=10.1038/nature11378;
RA   Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W., Zhang M.,
RA   Wright G., Shaffer A.L., Hodson D.J., Buras E., Liu X., Powell J.,
RA   Yang Y., Xu W., Zhao H., Kohlhammer H., Rosenwald A., Kluin P.,
RA   Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M.,
RA   Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B.,
RA   Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Pittaluga S., Wilson W.,
RA   Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.;
RT   "Burkitt lymphoma pathogenesis and therapeutic targets from structural
RT   and functional genomics.";
RL   Nature 490:116-120(2012).
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:E954893-E954893(2014).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=29892436; DOI=10.1098/rsos.172472;
RA   Shioda S., Kasai F., Watanabe K., Kawakami K., Ohtani A., Iemura M.,
RA   Ozawa M., Arakawa A., Hirayama N., Kawaguchi E., Tano T., Miyata S.,
RA   Satoh M., Shimizu N., Kohara A.;
RT   "Screening for 15 pathogenic viruses in human cell lines registered at
RT   the JCRB Cell Bank: characterization of in vitro human cells by viral
RT   infection.";
RL   R. Soc. Open Sci. 5:172472-172472(2018).
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940-940(2018).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).